Bevacizumab for advanced breast cancer Journal Article
| Authors: | Traina, T. A.; Rugo, H. S.; Dickler, M. |
| Article Title: | Bevacizumab for advanced breast cancer |
| Abstract: | Tumor angiogenesis is essential for the growth and metastasis of solid tumors. In breast cancer, increased levels of vascular endothelial growth factor (VEGF) have been associated with poor prognosis in lymph node-positive and lymph node-negative patients. In addition to its prognostic significance, VEGF is now a validated target in the treatment of breast cancer. Bevacizumab, an anti-VEGF antibody, has demonstrated significant clinical benefit in several solid tumors. In this article the authors discuss the data pertaining to bevacizumab and other antiangiogenic agents for the treatment of patients who have advanced breast cancer. © 2007 Elsevier Inc. All rights reserved. |
| Keywords: | signal transduction; vasculotropin; cancer survival; treatment response; vascular endothelial growth factor a; unclassified drug; overall survival; clinical trial; drug activity; fatigue; neutropenia; review; bevacizumab; doxorubicin; erlotinib; advanced cancer; cancer growth; diarrhea; drug efficacy; drug safety; drug withdrawal; hypertension; monotherapy; nonhuman; side effect; treatment duration; drug targeting; capecitabine; gemcitabine; paclitaxel; adjuvant therapy; cytarabine; methotrexate; carboplatin; multiple cycle treatment; breast cancer; bleeding; leukopenia; nausea; neuropathy; stomatitis; vomiting; myalgia; combination chemotherapy; cyclophosphamide; drug effect; angiogenesis; breast neoplasms; neovascularization, pathologic; docetaxel; arthralgia; asthenia; chill; dizziness; drug dose escalation; dyspnea; fever; pruritus; rash; lung embolism; hypotension; antibodies, monoclonal; rigor; thorax pain; adverse outcome; drug mechanism; dosage schedule comparison; thromboembolism; vein thrombosis; cardiotoxicity; thrombosis; mitoxantrone; neoplasm metastasis; soft tissue sarcoma; drug clearance; colitis; pleura effusion; headache; letrozole; liver function test; intestine obstruction; drug half life; trastuzumab; navelbine; angiogenesis inhibitors; pericardial effusion; bacterial infection; digestive system perforation; wound healing impairment; epistaxis; congestive heart failure; proteinuria; lung infiltrate; artery thrombosis; nephrotic syndrome; leukoencephalopathy; clinical trials; urticaria; heart function; hypertension encephalopathy; enzyme blood level; paclitaxel derivative; menstrual cycle; growth factor receptor; nanoparticle albumin bound paclitaxel |
| Journal Title: | Hematology/Oncology Clinics of North America |
| Volume: | 21 |
| Issue: | 2 |
| ISSN: | 0889-8588 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2007-04-01 |
| Start Page: | 303 |
| End Page: | 319 |
| Language: | English |
| DOI: | 10.1016/j.hoc.2007.03.006 |
| PUBMED: | 17512451 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 19" - "Export Date: 17 November 2011" - "CODEN: HCNAE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work